Adaptimmune Therapeutics (ADAP) Stock Rating Reaffirmed by Cowen

Share on StockTwits

Cowen restated their buy rating on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report published on Tuesday.

A number of other equities research analysts have also weighed in on ADAP. Zacks Investment Research upgraded shares of Adaptimmune Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 7th. Raymond James decreased their price objective on shares of Adaptimmune Therapeutics from $20.00 to $16.00 and set a buy rating for the company in a report on Monday, October 22nd. ValuEngine lowered shares of Adaptimmune Therapeutics from a strong-buy rating to a buy rating in a report on Monday, October 22nd. BidaskClub upgraded shares of Adaptimmune Therapeutics from a hold rating to a buy rating in a report on Saturday, September 29th. Finally, TheStreet lowered shares of Adaptimmune Therapeutics from a c- rating to a d+ rating in a report on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of Buy and an average target price of $15.44.

Shares of ADAP stock traded down $0.48 during trading hours on Tuesday, reaching $6.18. 682,929 shares of the stock were exchanged, compared to its average volume of 795,120. Adaptimmune Therapeutics has a 12-month low of $5.73 and a 12-month high of $14.63. The stock has a market cap of $627.87 million, a PE ratio of -7.73 and a beta of 2.02.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 41.63%. The firm had revenue of $40.79 million during the quarter, compared to analysts’ expectations of $29.41 million. On average, equities research analysts predict that Adaptimmune Therapeutics will post -0.98 earnings per share for the current fiscal year.

In other news, major shareholder Enterprise Associates 14 New acquired 3,000,000 shares of Adaptimmune Therapeutics stock in a transaction that occurred on Friday, September 7th. The stock was purchased at an average price of $1.67 per share, for a total transaction of $5,010,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total transaction of $256,250.00. The disclosure for this sale can be found here. Insiders own 26.47% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of ADAP. Stanley Laman Group Ltd. bought a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth approximately $7,665,000. Frontier Capital Management Co. LLC raised its stake in shares of Adaptimmune Therapeutics by 351.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 698,694 shares of the biotechnology company’s stock worth $9,474,000 after acquiring an additional 543,809 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of Adaptimmune Therapeutics by 18.2% during the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock worth $36,005,000 after acquiring an additional 467,852 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Adaptimmune Therapeutics by 786.0% during the 1st quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after acquiring an additional 164,704 shares in the last quarter. Finally, Bellevue Group AG bought a new position in shares of Adaptimmune Therapeutics during the 2nd quarter worth approximately $711,000. Hedge funds and other institutional investors own 58.99% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Featured Article: Day Trading

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply